JP2002510652A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510652A5
JP2002510652A5 JP2000542041A JP2000542041A JP2002510652A5 JP 2002510652 A5 JP2002510652 A5 JP 2002510652A5 JP 2000542041 A JP2000542041 A JP 2000542041A JP 2000542041 A JP2000542041 A JP 2000542041A JP 2002510652 A5 JP2002510652 A5 JP 2002510652A5
Authority
JP
Japan
Prior art keywords
intravascular
preferred
present
formulations
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000542041A
Other languages
English (en)
Japanese (ja)
Other versions
JP4664499B2 (ja
JP2002510652A (ja
Filing date
Publication date
Priority claimed from US09/057,143 external-priority patent/US6136799A/en
Application filed filed Critical
Publication of JP2002510652A publication Critical patent/JP2002510652A/ja
Publication of JP2002510652A5 publication Critical patent/JP2002510652A5/ja
Application granted granted Critical
Publication of JP4664499B2 publication Critical patent/JP4664499B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000542041A 1998-04-08 1999-03-22 共溶媒処方物 Expired - Lifetime JP4664499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/057,143 1998-04-08
US09/057,143 US6136799A (en) 1998-04-08 1998-04-08 Cosolvent formulations
PCT/US1999/006196 WO1999051271A2 (en) 1998-04-08 1999-03-22 Compositions comprising glycol derivatives and alcohols

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010207684A Division JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物

Publications (3)

Publication Number Publication Date
JP2002510652A JP2002510652A (ja) 2002-04-09
JP2002510652A5 true JP2002510652A5 (enExample) 2010-11-18
JP4664499B2 JP4664499B2 (ja) 2011-04-06

Family

ID=22008769

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000542041A Expired - Lifetime JP4664499B2 (ja) 1998-04-08 1999-03-22 共溶媒処方物
JP2010207684A Expired - Lifetime JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物
JP2014016658A Expired - Lifetime JP5887368B2 (ja) 1998-04-08 2014-01-31 共溶媒処方物
JP2015204318A Pending JP2016053046A (ja) 1998-04-08 2015-10-16 共溶媒処方物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010207684A Expired - Lifetime JP5548079B2 (ja) 1998-04-08 2010-09-16 共溶媒処方物
JP2014016658A Expired - Lifetime JP5887368B2 (ja) 1998-04-08 2014-01-31 共溶媒処方物
JP2015204318A Pending JP2016053046A (ja) 1998-04-08 2015-10-16 共溶媒処方物

Country Status (11)

Country Link
US (2) US6136799A (enExample)
EP (1) EP1073467B1 (enExample)
JP (4) JP4664499B2 (enExample)
AT (1) ATE275974T1 (enExample)
AU (1) AU758989B2 (enExample)
CA (1) CA2326198C (enExample)
DE (1) DE69920201T2 (enExample)
DK (1) DK1073467T3 (enExample)
ES (1) ES2229693T3 (enExample)
PT (1) PT1073467E (enExample)
WO (1) WO1999051271A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
DE60128149D1 (en) * 2000-11-07 2007-06-06 Univ North Carolina State Putrescin-n-methyltransferasepromotor
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
ATE418347T1 (de) 2002-02-19 2009-01-15 Resolution Chemicals Ltd Auf lösungsmitteln basierende sterilisation von steroiden
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20070149489A1 (en) * 2005-07-18 2007-06-28 Anchel Schwartz Preparation of paricalcitol
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
MX2008014418A (es) * 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2545940A1 (de) * 2011-07-14 2013-01-16 hameln rds gmbh Parenterale Zusammensetzungen
HK1206600A1 (en) 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
ES2698403T3 (es) * 2012-12-27 2019-02-04 Pharmathen Sa Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
CN106265492B (zh) * 2015-06-04 2020-12-11 成都国为生物医药有限公司 一种含有帕立骨化醇的药物组合物及其制备方法
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4212886A (en) * 1978-11-01 1980-07-15 Survival Technology, Inc. Stabilized benactyzine hydrochloride
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
DE3316510A1 (de) * 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US4594340A (en) * 1984-11-29 1986-06-10 Hoffmann-La Roche Inc. 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
AU649057B2 (en) * 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
DE69228814T2 (de) * 1991-06-28 1999-11-11 Hairbiotech, Inc. Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
GB9201920D0 (en) * 1992-01-29 1992-03-18 Leo Pharm Prod Ltd Novel treatment i
JPH05246891A (ja) * 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
KR960013798B1 (ko) * 1992-04-24 1996-10-10 재단법인 한국전자통신연구소 평면 도파로형 공간 스위치
AU5861396A (en) * 1995-05-19 1996-11-29 Abbott Laboratories Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
ATE227564T1 (de) * 1996-04-04 2002-11-15 Cilag Ag Topische vitamin d zusammensetzung auf liposomenbasis
DK0893121T3 (da) * 1997-06-27 2002-06-17 Akzo Nobel Nv Flydende oral medicinopløsning
CA2211949A1 (en) * 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations

Similar Documents

Publication Publication Date Title
JP2002510652A5 (enExample)
ES2567716T3 (es) Formulaciones que contienen amiodarona y sulfoalquil éter ciclodextrina
KR102699155B1 (ko) 단트롤렌을 포함하는 수성 조성물
CA2066731A1 (en) Liquid oral pharmaceutical compositions having anti-inflammatory activity
JP2004529934A5 (enExample)
AU8110498A (en) Pharmaceutical formulations containing voriconazole
CZ25793A3 (en) Pharmaceutical mixtures of phlorphenicol
JP6349057B2 (ja) オロパタジン含有水性組成物
ES2359856T3 (es) Formulación parenteral estable que contiene un inhibidor de vsr de una estructura de benzodiazepina.
WO2002102383A1 (fr) Preparation de cilostazol aqueuse pour injections
JP2012167132A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
ES2272720T3 (es) Formulacion de esmolol.
JP5847942B2 (ja) タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JP5113323B2 (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
JP5226220B2 (ja) 非経口投与を目的とするビンフルニンの医薬組成物、その調製方法およびその使用
JP2006312628A (ja) アシタザノラスト含有水性組成物
WO2019097413A1 (en) Stable non-aqueous pharmaceutical compositions
ES2375784B1 (es) Gel de ácido tranexámico
WO2021090183A1 (en) Liquid melphalan composition
WO2009150278A1 (es) Una composición farmacéutica de melfalano
JP2007514778A5 (enExample)
JP5205909B2 (ja) 粘膜適用液剤
JP2006151968A (ja) オキシメタゾリン含有水性組成物
CN103800910B (zh) 可消除Tween类表面活性剂起昙现象的组合物